{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-24-012242","form_type":"8-K","ticker":"WINT","cik":"0000946486","company_name":"WINDTREE THERAPEUTICS INC /DE/","filed_at":"2024-04-17T23:59:59+00:00","discovered_at":"2026-05-14T18:03:22.574304+00:00","generated_at":"2026-06-03T22:00:51.329147+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Windtree Therapeutics reports Q4 2023 net loss of $5.2M; cash only $4.3M as of Dec 31","bullets":["Q4 net loss $5.2M ($0.95 per share) vs $9.7M ($13.01) in Q4 2022; FY net loss $20.3M ($5.24 per share).","Cash and equivalents $4.3M at Dec 31, 2023; completed $1.5M convertible note bridge in April 2024 to fund operations through April.","Acquired novel aPKCi inhibitor platform from Varian Biopharmaceuticals; includes topical and oral formulations.","Licensed istaroxime and other CV assets to Lee's Pharmaceutical for Greater China; eligible for up to $138M milestones plus royalties.","Two Phase 2 istaroxime trials in cardiogenic shock ongoing; data expected H2 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-24-012242","json":"https://secwatch.observer/filing/0001437749-24-012242.json","markdown":"https://secwatch.observer/filing/0001437749-24-012242.md","text":"https://secwatch.observer/filing/0001437749-24-012242.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/946486/000143774924012242/0001437749-24-012242-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/946486/000143774924012242/wint20231117_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-03T22:00:51.329147+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"e60fa4f4fd693054259b3fc696843b5de5ce3069","claim":"WINDTREE THERAPEUTICS INC /DE/ reported financial results for the fourth quarter and fiscal year ended December 31, 2023.","evidence_excerpt":"On April 17, 2024, Windtree Therapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the fourth quarter and fiscal year ended December 31, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/946486/000143774924012242/0001437749-24-012242-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fourth quarter and fiscal year ended December 31, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}